GLP1R and Parkinson disease: Badawi et al. [51] demonstrated that both sitagliptin (DPP-4 inhibitor) and liraglutide (GLP-1 agonist) elevated the striatal dopamine level, which could be helpful in the treatment of Parkinson’s disease [51].